1863. RBX2660 is Safe, Superior to Antibiotic-Treated Controls for Preventing Recurrent Clostridium difficile, and May Rehabilitate Patient Microbiomes: Open Label Trial Results
Session: Poster Abstract Session: Clinical Study with New Antibiotics and Antifungals
Saturday, October 7, 2017
Room: Poster Hall CD
Background:  Effective treatment options for recurrent C. difficile infection (rCDI) are limited, with high recurrence rates associated with the current standard of care. RBX2660, a standardized microbiota-based drug, was efficacious for preventing rCDI in a double-blinded Phase 2 clinical trial. Herein we report results from a subsequent open-label trial to evaluate the safety, efficacy, and microbiome altering-activity of RBX2660 for preventing rCDI.

Methods:  This prospective, multicenter, open-label Phase 2 study enrolled subjects who had experienced either ≥2 recurrences of CDI following standard-of-care antibiotic therapy or ≥2 episodes of severe CDI requiring hospitalization. Participants received up to 2 doses of RBX2660 delivered via enema with doses 7 days apart. Efficacy was defined as absence of CDI at 8 weeks from the last dose and was compared to the 8-week CDI-free rate of subjects who received antibiotic treatment alone in a matched historical control arm. 16s rRNA analysis was conducted on stool samples that were voluntarily submitted from RBX2660-treated subjects at baseline, 7, 30, and 60 days after treatment, and operational taxonomic units were compared longitudinally.

Results:  132 RBX2660 and 110 historical control subjects were included from 31 and 4 centers, respectively, in the USA and Canada. RBX2660’s efficacy in preventing rCDI (78.8%) was higher than CDI-free rates in the Historical Control group (51.8%, p<0.001). A total of 476 adverse events (AEs) were reported by 97 RBX2660 subjects (73.5%) compared to 691 AEs among 69 historical controls (62.7%). Following treatment, the diversity of the RBX2660 treated subjects’ microbiomes significantly increased and the relative proportion of Bacteroidia and Clostridia, while decreasing the relative proportion of Gammaproteobacteria. The resulting RBX2660-treated subject microbiota more closely resembled healthy donors than at study entry.

Conclusion:  This open-label Phase 2 study demonstrates RBX2660’s efficacy in preventing rCDI compared to an antibiotic-treated historical control group. The RBX2660 safety profile is consistent with results from previous clinical trials and microbiota analysis suggests that RBX2660 may rehabilitate patient microbiota.

This analysis was funded by Rebiotix Inc., Roseville, MN.

Robert Orenstein, DO, FIDSA, Infectious Diseases, Mayo Clinic Arizona, Phoenix, AZ, Erik R. Dubberke, MD, MSPH, Washington University, St Louis, MO, Sahil Khanna, MBBS, MS, Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, Gail Hecht, MD, Division of Gastroenterology and Nutrition, Loyola University Medical Center, Chicago, IL, Herbert Dupont, MD, UT School of Public Health, houston, TX, Christine Lee, MD, FRCPC, McMaster University, Hamilton, ON, Canada, Ken Blount, PhD, Rebiotix, Roseville, MN and Sharina Carter, PhD, BioRankings LLC, St. Louis, MO

Disclosures:

R. Orenstein, Rebiotix, Inc: Scientific Advisor , Consulting fee

E. R. Dubberke, Rebiotix, Inc.: Scientific Advisor , Consulting fee

S. Khanna, Rebiotix, Inc.: Scientific Advisor , Consulting fee

G. Hecht, Rebiotix, Inc.: Scientific Advisor , Consulting fee

H. Dupont, Rebiotix, Inc.: Investigator , Research support

C. Lee, Rebiotix, Inc.: Scientific Advisor , Consulting fee

K. Blount, Rebiotix, Inc.: Employee , Salary

S. Carter, Rebiotix, Inc.: Research Contractor , Consulting fee

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.